Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. Hyman DM, et al. Among authors: erinjeri jp. Nature. 2018 Feb 8;554(7691):189-194. doi: 10.1038/nature25475. Epub 2018 Jan 31. Nature. 2018. PMID: 29420467 Free PMC article. Clinical Trial.
Selective Intra-Arterial Doxorubicin Eluting Microsphere Embolization for Desmoid Fibromatosis: A Combined Prospective and Retrospective Study.
Elnekave E, Ben Ami E, Shamai S, Peretz I, Tamir S, Bruckheimer E, Stemmer A, Erinjeri J, Abu Quider A, Seidensticker M, Wildgruber M, Ricke J, Anazodo A, Fung KF, Zer A, Ash S. Elnekave E, et al. Cancers (Basel). 2022 Oct 14;14(20):5045. doi: 10.3390/cancers14205045. Cancers (Basel). 2022. PMID: 36291829 Free PMC article.
Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT.
Ulaner GA, Hyman DM, Ross DS, Corben A, Chandarlapaty S, Goldfarb S, McArthur H, Erinjeri JP, Solomon SB, Kolb H, Lyashchenko SK, Lewis JS, Carrasquillo JA. Ulaner GA, et al. Among authors: erinjeri jp. J Nucl Med. 2016 Oct;57(10):1523-1528. doi: 10.2967/jnumed.115.172031. Epub 2016 May 5. J Nucl Med. 2016. PMID: 27151988 Free PMC article. Clinical Trial.
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.
Smyth LM, Monson KR, Jhaveri K, Drilon A, Li BT, Abida W, Iyer G, Gerecitano JF, Gounder M, Harding JJ, Voss MH, Makker V, Ho AL, Razavi P, Iasonos A, Bialer P, Lacouture ME, Teitcher JB, Erinjeri JP, Katabi N, Fury MG, Hyman DM. Smyth LM, et al. Among authors: erinjeri jp. Invest New Drugs. 2017 Dec;35(6):742-750. doi: 10.1007/s10637-017-0445-0. Epub 2017 Mar 9. Invest New Drugs. 2017. PMID: 28281183 Free PMC article. Clinical Trial.
AKT Inhibition in Solid Tumors With AKT1 Mutations.
Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, Bando H, El-Khoueiry AB, Pérez-Fidalgo JA, Mita A, Schellens JHM, Chang MT, Reichel JB, Bouvier N, Selcuklu SD, Soumerai TE, Torrisi J, Erinjeri JP, Ambrose H, Barrett JC, Dougherty B, Foxley A, Lindemann JPO, McEwen R, Pass M, Schiavon G, Berger MF, Chandarlapaty S, Solit DB, Banerji U, Baselga J, Taylor BS. Hyman DM, et al. Among authors: erinjeri jp. J Clin Oncol. 2017 Jul 10;35(20):2251-2259. doi: 10.1200/JCO.2017.73.0143. Epub 2017 May 10. J Clin Oncol. 2017. PMID: 28489509 Free PMC article.
Adjuvant Medications That Improve Survival after Locoregional Therapy.
Boas FE, Ziv E, Yarmohammadi H, Brown KT, Erinjeri JP, Sofocleous CT, Harding JJ, Solomon SB. Boas FE, et al. Among authors: erinjeri jp. J Vasc Interv Radiol. 2017 Jul;28(7):971-977.e4. doi: 10.1016/j.jvir.2017.04.016. Epub 2017 May 17. J Vasc Interv Radiol. 2017. PMID: 28527884 Free PMC article.
Reply to: "Adjuvant Medications that Improve Survival after Locoregional Therapy".
Boas FE, Ziv E, Yarmohammadi H, Brown KT, Erinjeri JP, Sofocleous CT, Harding JJ, Solomon SB. Boas FE, et al. Among authors: erinjeri jp. J Vasc Interv Radiol. 2017 Sep;28(9):1335-1336. doi: 10.1016/j.jvir.2017.06.028. J Vasc Interv Radiol. 2017. PMID: 28841960 Free PMC article. No abstract available.
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, Raje NS, Wolf J, Erinjeri JP, Torrisi J, Lacouture M, Elez E, Martínez-Valle F, Durham B, Arcila ME, Ulaner G, Abdel-Wahab O, Pitcher B, Makrutzki M, Riehl T, Baselga J, Hyman DM. Diamond EL, et al. Among authors: erinjeri jp. JAMA Oncol. 2018 Mar 1;4(3):384-388. doi: 10.1001/jamaoncol.2017.5029. JAMA Oncol. 2018. PMID: 29188284 Free PMC article. Clinical Trial.
138 results